In:
Digestive Diseases, S. Karger AG, Vol. 36, No. 4 ( 2018), p. 264-268
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Our aims were to assess the real life effectiveness and safety of the new bismuth-containing quadruple therapy in a large population of patients infected by 〈 i 〉 Helicobacter pylori 〈 /i 〉 . 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Consecutive dyspeptic 〈 i 〉 H. pylori 〈 /i 〉 -positive patients were enrolled, both naïve for treatment and already unsuccessfully treated. Patients were treated with Pylera® 3 capsules 4 times/daily plus omeprazole 20 mg or esomeprazole 40 mg 2 times/daily for 10 days. Eradication was confirmed using a urea-breath test (at least 30 days after the end of the treatment). Efficacy and safety were assessed. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 A total of 349 patients were treated. 〈 i 〉 H. pylori 〈 /i 〉 eradication was achieved in 316 (90.5%, 95% CIs 80.8–1.0) patients in the intention-to-treat population, and in 93.5% (95% CIs 83.5–1.0) in the per-protocol population. No difference in the eradication rate was found between naïve and previously treated patients (91.3 vs. 90.0%, 〈 i 〉 p 〈 /i 〉 = 0.901). Adverse events occurred in 55 patients (15.8%, 95% CIs 11.9–20.1). Five patients discontinued treatment: 2 patients suffered from severe abdominal pain, one patient from headache, one patient from diarrhea, and one patient from diffuse urticarial rush. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Pylera® achieved a remarkable eradication rate in real life both as first treatment and as a rescue therapy, with a good safety profile.
Type of Medium:
Online Resource
ISSN:
0257-2753
,
1421-9875
Language:
English
Publisher:
S. Karger AG
Publication Date:
2018
detail.hit.zdb_id:
1482221-0
Permalink